Form 8-K - Current report:
SEC Accession No. 0001493152-25-014684
Filing Date
2025-09-23
Accepted
2025-09-23 17:30:50
Documents
13
Period of Report
2025-09-17
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 39682
2 EX-10.1 ex10-1.htm EX-10.1 14910
  Complete submission text file 0001493152-25-014684.txt   222692

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gtbp-20250917.xsd EX-101.SCH 3023
4 XBRL LABEL FILE gtbp-20250917_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE gtbp-20250917_pre.xml EX-101.PRE 22364
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3681
Mailing Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111
Business Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

EIN.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40023 | Film No.: 251334744
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)